AJP - Heart AJP: Lung Cellular and Molecular Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol (May 9, 2008). doi:10.1152/ajpheart.01350.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/1/H343    most recent
01350.2007v2
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ye, Y.
Right arrow Articles by Birnbaum, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ye, Y.
Right arrow Articles by Birnbaum, Y.
Submitted on November 18, 2007
Accepted on May 6, 2008

The role of eNOS, iNOS and NF{kappa}B in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin

Yumei Ye1, Juan D Martinez2, J. Regino Perez-Polo3, Yu Lin4, Barry F Uretsky2, and Yochai Birnbaum1*

1 Internal Medicine, University of Texas Medical Branch, Galveston, Texas, United States; Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States
2 Internal Medicine, University of Texas Medical Branch, Galveston, Texas, United States
3 Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, United States
4 Galveston, Texas, United States; Internal Medicine, University of Texas Medical Branch, Galveston, Texas, United States

* To whom correspondence should be addressed. E-mail: yobirnba{at}utmb.edu.

Objectives: Pretreatment with atorvastatin (ATV) reduces infarct size (IS) and increases myocardial expression of phosphorylated endothelial nitric oxide synthase (P-eNOS), inducible NOS (iNOS), and cycloxygenase-2 (COX2) in the rat. Inhibiting COX2 abolished the ATV-induced IS limitation without affecting P-eNOS and iNOS expression. We investigated: 1) whether 3-day ATV pretreatment limits IS in eNOS-/- and iNOS-/- mouse; 2) whether COX2 expression and/or activation by ATV is eNOS-, iNOS and/or NF{kappa}B-dependent. Methods: Male C57BL/6 wild-type (WT), University of North Carolina eNOS-/-, and iNOS-/- mice received ATV 10 mg/kg/d (ATV+) or water alone (ATV-) for 3 days. Mice underwent 30min coronary artery occlusion and 4h of reperfusion, or hearts were harvested and subjected to ELISA, immunoblotting, biotin switch and electrophoretic mobility shift assay (EMSA). Results: ATV reduced IS only in the WT mice. ATV increased eNOS, P-eNOS, iNOS and COX2 levels, and activated NF{kappa}B in WT mice. It also increased myocardial COX2 activity. In eNOS-/- mice, ATV increased COX2 expression, but not COX2 activity or iNOS expression. NF{kappa}B was not activated by ATV in the eNOS-/- mice. In the iNOS-/- mice eNOS and P-eNOS levels were increased, but not iNOS and COX2 levels; however, NF{kappa}B was activated. Conclusions: Both eNOS and iNOS are essential for the IS-limiting effect of ATV. Expression of COX2 by ATV is iNOS- but not eNOS- or NF{kappa}B dependent. Activation of COX2 is dependent on iNOS.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ye, Y. Lin, S. Manickavasagam, J. R. Perez-Polo, B. C. Tieu, and Y. Birnbaum
Pioglitazone protects the myocardium against ischemia-reperfusion injury in eNOS and iNOS knockout mice
Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2436 - H2446.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Matsumoto, E. Noguchi, K. Ishida, T. Kobayashi, N. Yamada, and K. Kamata
Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes
Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1165 - H1176.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.